These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 8017988)

  • 1. Long term treatment of polymyalgia rheumatica with deflazacort.
    Cimmino MA; Moggiana G; Montecucco C; Caporali R; Accardo S
    Ann Rheum Dis; 1994 May; 53(5):331-3. PubMed ID: 8017988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deflazacort versus methylprednisolone in polymyalgia rheumatica: clinical equivalence and relative antiinflammatory potency of different treatment regimens.
    Di Munno O; Imbimbo B; Mazzantini M; Milani S; Occhipinti G; Pasero G
    J Rheumatol; 1995 Aug; 22(8):1492-8. PubMed ID: 7473472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A longterm prospective study of the equipotency between deflazacort and prednisolone in the treatment of patients with polymyalgia rheumatica.
    Krogsgaard MR; Lund B; Johnsson B
    J Rheumatol; 1995 Sep; 22(9):1660-2. PubMed ID: 8523341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in bone mass during low dose corticosteroid treatment in patients with polymyalgia rheumatica: a double blind, prospective comparison between prednisolone and deflazacort.
    Krogsgaard MR; Thamsborg G; Lund B
    Ann Rheum Dis; 1996 Feb; 55(2):143-6. PubMed ID: 8712867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind study of deflazacort and prednisone in patients with chronic inflammatory disorders.
    Gray RE; Doherty SM; Galloway J; Coulton L; de Broe M; Kanis JA
    Arthritis Rheum; 1991 Mar; 34(3):287-95. PubMed ID: 2003854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Bone loss during low dose glucocorticoid treatment in patients with polymyalgia rheumatica. A double-blind, prospective comparison between prednisolone and deflazacort].
    Krogsgaard MR; Thamsborg G; Lund B
    Ugeskr Laeger; 1997 Jul; 159(30):4641-4. PubMed ID: 9245040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corticosteroid requirements in polymyalgia rheumatica.
    Weyand CM; Fulbright JW; Evans JM; Hunder GG; Goronzy JJ
    Arch Intern Med; 1999 Mar; 159(6):577-84. PubMed ID: 10090114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An initially double-blind controlled 96 week trial of depot methylprednisolone against oral prednisolone in the treatment of polymyalgia rheumatica.
    Dasgupta B; Dolan AL; Panayi GS; Fernandes L
    Br J Rheumatol; 1998 Feb; 37(2):189-95. PubMed ID: 9569075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment of the relative antiinflammatory potency of deflazacort and prednisone in polymyalgia rheumatica.
    Lund B; Egsmose C; Jørgensen S; Krogsgaard MR
    Calcif Tissue Int; 1987 Dec; 41(6):316-20. PubMed ID: 3124940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of methotrexate in polymyalgia rheumatica.
    Feinberg HL; Sherman JD; Schrepferman CG; Dietzen CJ; Feinberg GD
    J Rheumatol; 1996 Sep; 23(9):1550-2. PubMed ID: 8877923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymyalgia rheumatica can recur years after discontinuation of corticosteroid therapy.
    Docken WP
    Clin Exp Rheumatol; 2009; 27(1 Suppl 52):S25-7. PubMed ID: 19646342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A histomorphometric long-term longitudinal study of trabecular bone loss in glucocorticoid-treated patients: prednisone versus deflazacort.
    LoCascio V; Ballanti P; Milani S; Bertoldo F; LoCascio C; Zanolin EM; Bonucci E
    Calcif Tissue Int; 1998 Mar; 62(3):199-204. PubMed ID: 9501951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica.
    Gabriel SE; Sunku J; Salvarani C; O'Fallon WM; Hunder GG
    Arthritis Rheum; 1997 Oct; 40(10):1873-8. PubMed ID: 9336424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of refractory polymyalgia rheumatica with etanercept: an open pilot study.
    Catanoso MG; Macchioni P; Boiardi L; Pipitone N; Salvarani C
    Arthritis Rheum; 2007 Dec; 57(8):1514-9. PubMed ID: 18050171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current therapy of polymyalgia rheumatica.
    Gran JT
    Scand J Rheumatol; 1999; 28(5):269-72. PubMed ID: 10568422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months.
    Kyle V; Hazleman BL
    Ann Rheum Dis; 1989 Aug; 48(8):658-61. PubMed ID: 2782975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inappropriate modifications of corticosteroid therapy in polymyalgia rheumatica.
    Cimmino MA; Seriolo B; Accardo S
    Br J Rheumatol; 1994 Apr; 33(4):407. PubMed ID: 8156321
    [No Abstract]   [Full Text] [Related]  

  • 18. Polymyalgia rheumatica: clinical update.
    Ameer F; McNeil J
    Aust Fam Physician; 2014 Jun; 43(6):373-6. PubMed ID: 24897986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EULAR response criteria for polymyalgia rheumatica: results of an initiative of the European Collaborating Polymyalgia Rheumatica Group (subcommittee of ESCISIT).
    Leeb BF; Bird HA; Nesher G; Andel I; Hueber W; Logar D; Montecucco CM; Rovensky J; Sautner J; Sonnenblick M
    Ann Rheum Dis; 2003 Dec; 62(12):1189-94. PubMed ID: 14644857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The CRP initial response to treatment as prognostic factor in patients with polymyalgia rheumatica.
    Schreiber S; Buyse M
    Clin Rheumatol; 1995 May; 14(3):315-8. PubMed ID: 7641508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.